M. Cebey-López, M. Cebey-López, M. J. Currás-Tuala, M. J. Currás-Tuala, J. Gómez-Rial, J. Gómez-Rial, . . . F. Martinón-Torres. (2022). Case Report: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous heteroplasia. Frontiers Media S.A..
Chicago Style (17th ed.) CitationM. Cebey-López, et al. Case Report: Everolimus Reduced Bone Turnover Markers but Showed No Clinical Benefit in a Patient with Severe Progressive Osseous Heteroplasia. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationM. Cebey-López, et al. Case Report: Everolimus Reduced Bone Turnover Markers but Showed No Clinical Benefit in a Patient with Severe Progressive Osseous Heteroplasia. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.